Hemogenyx Pharmaceuticals PLC Announces Total Voting Rights

Rhea-AI Summary

Hemogenyx Pharmaceuticals plc announces its total issued share capital and voting rights as of March 28, 2024, consisting of 1,341,815,988 ordinary shares. Shareholders can use this figure for notification purposes under the Financial Conduct Authority's rules.

LONDON, UK / ACCESSWIRE / March 28, 2024 / Hemogenyx Pharmaceuticals plc ("Hemogenyx Pharmaceuticals" or the "Company") (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that the total issued share capital of the Company as at 28 March 2024 consists of 1,341,815,988 ordinary shares of 1 pence each, none of which are held in treasury. Therefore, the total number of voting rights in the Company is 1,341,815,988.

The figure of 1,341,815,988 ordinary shares may be used by shareholders of the Company as the denominator for the calculations by which they will determine if they are required to notify their investment in, or a change in their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Enquiries:

Hemogenyx Pharmaceuticals plc	https://hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder	headquarters@hemogenyx.com
Peter Redmond, Director	peter.redmond@hemogenyx.com
SP Angel Corporate Finance LLP	Tel: +44 (0)20 3470 0470
Matthew Johnson, Vadim Alexandre, Adam Cowl
Peterhouse Capital Limited	Tel: +44 (0)20 7469 0930
Lucy Williams, Duncan Vasey, Charles Goodfellow

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Hemogenyx Pharmaceuticals PLC

View the original press release on accesswire.com

FAQ

How many ordinary shares does Hemogenyx Pharmaceuticals plc have as of March 28, 2024?

Hemogenyx Pharmaceuticals plc has 1,341,815,988 ordinary shares as of March 28, 2024.

What is the total number of voting rights in Hemogenyx Pharmaceuticals plc?

The total number of voting rights in Hemogenyx Pharmaceuticals plc is 1,341,815,988.

Who can use the figure of 1,341,815,988 ordinary shares as a denominator for calculations?

Shareholders of Hemogenyx Pharmaceuticals plc can use the figure of 1,341,815,988 ordinary shares as a denominator for calculations.

Under which rules can shareholders determine if they need to notify their investment in Hemogenyx Pharmaceuticals plc?

Shareholders can determine if they need to notify their investment in Hemogenyx Pharmaceuticals plc under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.